NCT06323135|Completed
Nutrition Assessment in Advanced Cancer Patients
The Predictive Value of PG-SGA Criteria in Advanced Cancer Patients
Loading search results
The Predictive Value of PG-SGA Criteria in Advanced Cancer Patients
Sponsor study identifier
observational
2,115
1 country
1
Study Start
September 17, 2019
Actual (reported)Primary Completion
September 11, 2023
Actual (reported)Study Completion
September 11, 2023
Actual (reported)The goal of this retrospective observational study is to evaluate the prognostic value of nutrition assessment tool in advanced cancers. We aim to evaluate the clinical utility of nutrition assessment tool in predicting the clinical outcomes of cancer patients, which would help the clinicians to make tailored decision for this population.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
September 11, 2023
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 17, 2019
Actual (reported)September 11, 2023
Actual (reported)September 11, 2023
Actual (reported)March 14, 2024
Actual (reported)March 21, 2024
Actual (reported)All-cause mortality
the all-cause mortality of cancer patients
Nov 11, 2019 to 11 Sep, 2023
length of stay in hospital
Nov 11, 2019 to 11 Sep, 2023
In this study, all of the cancer types were reviewed. The histological information of cancer types was confirmed by the biopsy or resected surgical specimen. The tumor stages were classified based on the guidelines of the American Joint Committee on Cancer Manual (8th edition) (32) at the initial admission. Patients with the following clinical characteristics were excluded, such as those with incomplete nutritional evaluation, incomplete blood indicator test, and loss of follow-up. Furthermore, some cancer types with small sample sizes (\<20 cases) were also excluded from the analysis because of the study's validity concerns. Ultimately, eleven types of cancers (lung cancer, colorectal cancer, esophagus cancer, gastric cancer, head and neck cancer, pancreatic cancer, liver cancer, lymphoma, urinary cancer, breast cancer, and cancer with unknown primary sites) of interest were further investigated.
West China Hospital, Sichuan Universit
Chengdu, Sichuan, 610041, China
2,115 participants (actual enrollment reported by the registry).
First Submitted
March 14, 2024
First Posted
March 21, 2024
Study Start
September 17, 2019
Actual (reported)A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
Contact the study team to confirm eligibility.
Primary Completion
September 11, 2023
Actual (reported)Study Completion
September 11, 2023
Actual (reported)Last Updated
March 21, 2024
Record last verified: 2024-03
The data was confidential
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: